Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.
The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.
Teva posts a fourth-quarter earnings miss and issues lower-than-expected guidance for 2019.
Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.
Shares surge after a report says London-based Smith & Nephew is considering buying the company.
Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.